GH Research PLC's GH001 Meets Phase 2a Endpoints, FDA Hold Addressed

Ticker: GHRS · Form: 6-K · Filed: Jan 10, 2025 · CIK: 1855129

Sentiment: bullish

Topics: clinical-trials, fda, drug-development

TL;DR

GH Research PLC's GH001 drug hits Phase 2a targets, FDA hold cleared with no toxicity issues found.

AI Summary

On January 10, 2025, GH Research PLC announced that its drug candidate GH001 met its primary endpoint in two Phase 2a Proof-of-Concept (POC) trials. The company also completed all FDA requests to address an Investigational New Drug (IND) hold, with no findings of respiratory toxicity in non-rodent studies. An updated investor presentation was made available on their website.

Why It Matters

This news is significant as it indicates positive clinical trial results for GH001 and progress in resolving regulatory hurdles, potentially moving the drug closer to further development stages.

Risk Assessment

Risk Level: medium — While positive, the results are from Phase 2a trials, and further development and regulatory approvals are still required, carrying inherent risks.

Key Players & Entities

FAQ

What were the primary endpoints met in the two Phase 2a POC trials for GH001?

The filing states that the primary endpoints were met, but does not specify what those endpoints were.

What specific FDA requests were addressed to lift the IND hold?

The filing mentions that all FDA requests to address the IND hold were completed, but does not detail the specific requests.

What is the significance of 'no findings of respiratory toxicity in non-rodents'?

This finding is significant because it addresses a potential safety concern that may have contributed to the IND hold, indicating a potentially safer profile for GH001 in non-rodent species.

Where can the updated investor presentation be accessed?

The updated investor presentation was made available on the company's website.

What is the Commission File Number for GH Research PLC?

The Commission File Number for GH Research PLC is 001-40530.

Filing Stats: 397 words · 2 min read · ~1 pages · Grade level 13.1 · Accepted 2025-01-10 07:06:28

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K On January 10, 2025, GH Research PLC (the "Company") announced primary endpoint met in two phase 2a POC trials with GH001 and completion of all FDA requests to address IND hold with no findings of respiratory toxicity in non-rodents, and made available an updated investor presentation on its website. A copy of the press release is exhibited hereto as Exhibit 99.1 and a copy of the investor presentation is attached hereto as Exhibit 99.2 . The fact that this press release and investor presentation is being made available and furnished herewith should not be deemed an admission as to the materiality of any information contained in the materials. The information contained in the press release and investor presentation is being provided as of January 10, 2025, and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking 1 INCORPORATION BY REFERENCE This Report on Form 6-K (other than Exhibit 99.2 hereto), including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the registration statement on Form S-8 (Registration No. 333-270422) and the registration statement on Form F-3 (Registration No 333-270418) of the Company and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 2 EXHIBIT INDEX Exhibit No. Description 99.1 Press release dated January 10, 2025 99.2 Corporate Presentation for January 2025 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GH Research PLC Date: January 10, 2025 By: /s/ Julie Ryan Name: Julie Ryan Title: Vice President, Finance 4

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing